Friso Calkoen

568 total citations
28 papers, 148 citations indexed

About

Friso Calkoen is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Friso Calkoen has authored 28 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Hematology and 8 papers in Genetics. Recurrent topics in Friso Calkoen's work include CAR-T cell therapy research (12 papers), Hematopoietic Stem Cell Transplantation (9 papers) and Virus-based gene therapy research (5 papers). Friso Calkoen is often cited by papers focused on CAR-T cell therapy research (12 papers), Hematopoietic Stem Cell Transplantation (9 papers) and Virus-based gene therapy research (5 papers). Friso Calkoen collaborates with scholars based in Netherlands, United States and Spain. Friso Calkoen's co-authors include Maarten J. D. van Tol, Lynne M. Ball, Monique M. van Ostaijen-ten Dam, Peter Bader, R. Maarten Egeler, R. ten Cate, D. M. C. Brinkman, Lisanne S. Vijfhuizen, Franco Locatelli and Astrid G. S. van Halteren and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Friso Calkoen

25 papers receiving 146 citations

Peers

Countries citing papers authored by Friso Calkoen

Since Specialization

Citations

This map shows the geographic impact of Friso Calkoen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friso Calkoen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friso Calkoen more than expected).

Fields of papers citing papers by Friso Calkoen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friso Calkoen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friso Calkoen. The network helps show where Friso Calkoen may publish in the future.

Co-authorship network of co-authors of Friso Calkoen

This figure shows the co-authorship network connecting the top 25 collaborators of Friso Calkoen. A scholar is included among the top collaborators of Friso Calkoen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Friso Calkoen. Friso Calkoen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), Tineke Aarts‐Riemens, (unknown), (unknown), Rob C. Hoeben, Trudy Straetemans, Esther Hulleman, Friso Calkoen, Jasper van der Lugt, Jürgen Kuball	2
2	Multimodal analysis of pediatric pilocytic astrocytomas reveals tumor location-associated cellular and transcriptional heterogeneity 2025 ·Neuro-Oncology ·(unknown), (unknown), Friso Calkoen, (unknown), (unknown), Tiago Carvalheiro, (unknown), Robyn D. Gartrell, Dannis G van Vuurden, Henk G. Stunnenberg, Eelco W. Hoving, Pieter Wesseling, Jasper van der Lugt, Mariëtte E.G. Kranendonk, Lennart Kester	1
3	Excellent Outcomes in Patients Receiving Tisagenlecleucel for R/R B-Cell ALL: Results from the European Post-Authorization Safety Study (PASS), on Behalf of the Ctiwp, PDWP and ALWP of the EBMT. 2025 ·Transplantation and Cellular Therapy ·Krzysztof Kałwak, Annalisa Ruggeri, (unknown), (unknown), Isabel Sánchez‐Ortega, Chiara Bonini, Éolia Brissot, Tayfun Güngör, Peter Bader, Friso Calkoen, Henrik Sengeloev, Michael Daskalakis, Stephen Robinson, (unknown), Emma Nicholson, Anne Sîrvent, Jürgen Kuball, Fabio Ciceri, Christian Chabannon, (unknown)	0
4	OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Friso Calkoen, Jasper van der Lugt, Esther Hulleman	3
5	BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response 2024 ·Nature Protocols ·María Alieva, (unknown), Sam de Blank, (unknown), Amber L. Zeeman, (unknown), Annelisa M. Cornel, Cesca van de Ven, Rob Pieters, Monique L. den Boer, Stefan Nierkens, Friso Calkoen, Hans Clevers, Jürgen Kuball, Zsolt Sebestyén, Ellen J. Wehrens, Johanna F. Dekkers, Anne C. Rios	9
6	The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Dennis S. Metselaar, Michaël H. Meel, (unknown), Bernadette G. van den Hoogen, Rob C. Hoeben, E. Antonio Chiocca, William F. Goins, (unknown), Yunlei Li, Marta M. Alonso, Friso Calkoen, Esther Hulleman, Jasper van der Lugt, Martine L.M. Lamfers	5
7	Omnigene-Guttm ensures fecal microbiome stability in the pediatric population 2024 ·AMB Express ·(unknown), (unknown), Hyun-ju Lee, Sabine Mueller, Cassie Kline, John Bianco, Janetta Top, Marcel R. de Zoete, Lennart Kester, Friso Calkoen, Jasper van der Lugt	0
8	Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Annelisa M. Cornel, (unknown), Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso Calkoen, Stefan Nierkens, Frank N. van Leeuwen	2
9	LGG-15. SINGLE-NUCLEUS AND BULK RNA SEQUENCING OF PEDIATRIC PILOCYTIC ASTROCYTOMAS REVEALS CNS LOCATION-ASSOCIATED TUMOR CELL AND MICROENVIRONMENTAL HETEROGENEITY 2023 ·Neuro-Oncology ·(unknown), (unknown), Mariëtte E.G. Kranendonk, Antoinette Y. N. Schouten‐van Meeteren, Lisethe Meijer, Friso Calkoen, Eelco W. Hoving, Pieter Wesseling, Jasper van der Lugt, Lennart Kester	1
10	Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing 2023 ·Cancer Immunology Immunotherapy ·Willem de Koning, (unknown), Friso Calkoen, Jasper van der Lugt, Lennart Kester, Dana A. M. Mustafa	0
11	INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities 2023 ·Transplantation and Cellular Therapy ·John A. Ligon, Sneha Ramakrishna, Francesco Ceppi, Friso Calkoen, Caroline Diorio, Kara L. Davis, Elad Jacoby, Stephen Gottschalk, Liora M. Schultz, Christian M. Capitini	2
12	Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia 2022 ·Leukemia ·(unknown), Erica Brivio, Harm van Tinteren, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, Monica López‐Duarte, Bianca F. Goemans, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan	13
13	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? 2022 ·Frontiers in Pediatrics ·Jochen Buechner, Ignazio Caruana, Annette Künkele, Susana Rives, Kim Vettenranta, Peter Bader, Christina Peters, André Baruchel, Friso Calkoen	16
14	A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies 2022 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), (unknown), Stefan Nierkens, Mariëtte E.G. Kranendonk, Lennart Kester, Friso Calkoen, Jasper van der Lugt	3
15	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward 2021 ·Cancers ·(unknown), Inge van der Werf, Friso Calkoen, Stefan Nierkens, Gertjan J.L. Kaspers, C. Michel Zwaan, Olaf Heidenreich	6
16	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia 2021 ·Blood ·(unknown), Erica Brivio, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, José Luís Fuster, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan	2
17	Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia 2015 ·Haematologica ·Friso Calkoen, (unknown), Else Eising, Lisanne S. Vijfhuizen, Peter A.C. ’t Hoen, Marry M. van den Heuvel‐Eibrink, R. Maarten Egeler, Maarten J. D. van Tol, L.M. Ball	4
18	Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro 2015 ·Stem Cell Research ·Friso Calkoen, (unknown), Melissa van Pel, Válerie de Haas, Lisanne S. Vijfhuizen, Else Eising, Wilma G. M. Kroes, Peter A.C. ’t Hoen, Marry M. van den Heuvel‐Eibrink, R. Maarten Egeler, Maarten J. D. van Tol, L.M. Ball	15
19	Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses 2013 ·Cytotherapy ·Friso Calkoen, D. M. C. Brinkman, (unknown), Monique M. van Ostaijen-ten Dam, R. ten Cate, Maarten J. D. van Tol, Lynne M. Ball	19
20	Gastrointestinal Acute Graft-versus-Host Disease in Children: Histology for Diagnosis, Mesenchymal Stromal Cells for Treatment, and Biomarkers for Prediction of Response 2013 ·Biology of Blood and Marrow Transplantation ·Friso Calkoen, Cornelia M. Jol‐van der Zijde, M. Luisa Mearin, Joachim J. Schweizer, Anja M. Jansen-Hoogendijk, Helene Roelofs, Astrid G. S. van Halteren, R. Maarten Egeler, Maarten J. D. van Tol, Lynne M. Ball	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact